- Home
- MRT vs THRD Comparison
MRT vs THRD Comparison
Compare MRT & THRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRT
- THRD
- Stock Information
- Founded
- MRT 2018
- THRD 2019
- Country
- MRT Turkey
- THRD United States
- Employees
- MRT N/A
- THRD N/A
- Industry
- MRT Rental/Leasing Companies
- THRD Biotechnology: Pharmaceutical Preparations
- Sector
- MRT Consumer Discretionary
- THRD Health Care
- Exchange
- MRT Nasdaq
- THRD Nasdaq
- Market Cap
- MRT 228.0M
- THRD 238.7M
- IPO Year
- MRT N/A
- THRD 2022
- Fundamental
- Price
- MRT $2.99
- THRD $5.46
- Analyst Decision
- MRT Strong Buy
- THRD Hold
- Analyst Count
- MRT 2
- THRD 3
- Target Price
- MRT $6.00
- THRD $5.00
- AVG Volume (30 Days)
- MRT 88.9K
- THRD 217.6K
- Earning Date
- MRT 01-01-0001
- THRD 08-07-2025
- Dividend Yield
- MRT N/A
- THRD N/A
- EPS Growth
- MRT N/A
- THRD N/A
- EPS
- MRT N/A
- THRD N/A
- Revenue
- MRT $18,659,655.00
- THRD N/A
- Revenue This Year
- MRT $83.29
- THRD N/A
- Revenue Next Year
- MRT $106.66
- THRD N/A
- P/E Ratio
- MRT N/A
- THRD N/A
- Revenue Growth
- MRT N/A
- THRD N/A
- 52 Week Low
- MRT $1.32
- THRD $3.18
- 52 Week High
- MRT $3.89
- THRD $16.02
- Technical
- Relative Strength Index (RSI)
- MRT 51.40
- THRD 66.73
- Support Level
- MRT $2.86
- THRD $5.42
- Resistance Level
- MRT $3.04
- THRD $5.45
- Average True Range (ATR)
- MRT 0.15
- THRD 0.04
- MACD
- MRT 0.03
- THRD -0.01
- Stochastic Oscillator
- MRT 63.33
- THRD 50.00
About MRT Marti Technologies Inc.
Marti Technologies Inc is a mobility app, offering multiple transportation services to its riders. Marti operates a ride-hailing service that matches riders with car, motorcycle, and taxi drivers, and operates a large fleet of rental e-mopeds, e-bikes, and e-scooters. All of Marti's offerings are serviced by proprietary software systems and IoT infrastructure.
About THRD Third Harmonic Bio Inc.
Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.